Start
Entdecken
nav.journalClub
Trends
Mehr
synapse
⌘+K
Sprache
Deutsch
Deutsch
Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial | Synapse
March 3, 2026
Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial
SP
Serena Porcari
CC
Chiara CICCARESE
Università Cattolica del Sacro Cuore
VH
Vitor Heidrich
University of Trento
See all
Key Points
Fecal microbiota transplantation may improve responses in patients with metastatic renal cell carcinoma.
The overall response rate was assessed, revealing promising outcomes in treatment groups.
Randomized phase 2 trial design with comparative analysis of treatment efficacy and safety.
This study emphasizes potential synergistic effects, indicating combined therapy may enhance treatment results.
Mark Helpful
Like
Save
Bookmark
Relay
Share
Mark Helpful
Like
Save
Bookmark
Relay
Share
Cite This Study
Copy
Porcari et al. (Wed,) studied this question.
synapsesocial.com/papers/69a75baac6e9836116a236fc
https://doi.org/https://doi.org/10.1038/s41591-025-04189-2